These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22179417)

  • 1. Persistence with intravenous zoledronate in elderly patients with osteoporosis.
    Lee YK; Nho JH; Ha YC; Koo KH
    Osteoporos Int; 2012 Sep; 23(9):2329-33. PubMed ID: 22179417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous zoledronic acid for the treatment of osteoporosis.
    Lewiecki EM
    Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.
    Hamdy RC
    Drug Des Devel Ther; 2010 Nov; 4():321-35. PubMed ID: 21151620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.
    Curtis JR; Yun H; Matthews R; Saag KG; Delzell E
    Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1054-60. PubMed ID: 22328117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
    Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
    Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern.
    Kaur U; Chakrabarti SS; Gambhir IS
    Curr Drug Saf; 2016; 11(3):267-9. PubMed ID: 27113952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].
    Hagino H; Hashimoto J; Okano T; Katagiri H
    Clin Calcium; 2008 Aug; 18(8):1176-82. PubMed ID: 18677057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects.
    Duke Med Health News; 2014 Mar; 20(3):1-2. PubMed ID: 24683617
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
    Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature.
    Umunakwe OC; Herren D; Kim SJ; Kohanim S
    Digit J Ophthalmol; 2017; 23(4):18-21. PubMed ID: 29403337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.
    Lafage-Proust MH
    Kidney Int; 2008 Sep; 74(5):557-9. PubMed ID: 18709026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of history of oral bisphosphonates on the incidence rate of fever after intravenous injection of zoledronic acid in patients with osteoporosis].
    Wang H; Hu ZH; Chen L; Pan Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):680-682. PubMed ID: 29263512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of acute anterior uveitis after intravenous zoledronate.
    Patel DV; Horne A; House M; Reid IR; McGhee CN
    Ophthalmology; 2013 Apr; 120(4):773-6. PubMed ID: 23290982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2002 Jul; 3(7):1007-9. PubMed ID: 12083999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
    Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
    HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Re-challenge in Patients with a History of Acute Anterior Uveitis Following Intravenous Zoledronate.
    Patel DV; Horne A; Mihov B; Stewart A; Reid IR; McGhee CN
    Calcif Tissue Int; 2015 Jul; 97(1):58-61. PubMed ID: 26001948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
    Nelson A; Fenlon D; Morris J; Sampson C; Harrop E; Murray N; Wheatley D; Hood K; Griffiths G; Barrett-Lee P
    Trials; 2013 Oct; 14():325. PubMed ID: 24107437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction].
    Lebret T; Mouysset JL; Lortholary A; Kouri CE; Bastit L; Ktiouet M; Khemaies S; Murraciole X; Guérif S
    Bull Cancer; 2013 Mar; 100(3):247-57. PubMed ID: 23518272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.